ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Investigation of circulating miR-182-3p, miR -382-3p and miR -93, miR -142-3p involved in tamoxifen resistance and sensitivity in luminal-subtype breast cancer patients: a case-control study.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Non-coding RNAs as regulators of chromosomal instability in breast cancer.Frontiers in oncology · 2026Review
- Interplay Between MicroRNAs and Breast Cancer Therapies: Personalized Therapeutic Potential for HER2-Low Breast Cancer.Cancers · 2025Review
- Examining the Role of Matrix Metalloproteinase-2 and MicroRNAs Regulation in Breast Cancer.The breast journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) commonly expresses estrogen receptors (ERs); hence, endocrine therapy targeting ERs is considered an effective treatment. Tamoxifen (TAM) resistance is an essential clinical complication leading to cancer progression and metastasis. This study investigated MicroRNAs (miRNAs) potentially implicated in drug resistance (miR-182-3p, miR-382-3p) or sensitivity (miR-93, miR- 142- 3p). This study aimed to provide new insights into serum microRNA expression profiles in BC. This case-control study included patients with luminal-A BC who received TAM for approximately one year. The case and control groups included 40 patients with or without local recurrence or metastasis. The expression levels of miR-182-3p, miR-382-3p, miR-93, and miR-142-3p in plasma samples were measured using real-time PCR with target-specific primers. The multivariate model of miR-93 (p = 0.0002), miR-182-3p (p = 0.0002), and miR-382-3p (p = 0.0028) demonstrated higher predictive power for TAM resistance. The only significant association was observed between miR-382-3p expression and lymphovascular invasion (LVI) (p = 0.0314). Moreover, lower expression levels of miR-93 and miR-382-3p were observed in the TAM-sensitive group compared to the TAM-resistant counterparts (p = 0.0002 and p = 0.0028, respectively). In contrast, the expression level of miR-182-3p was significantly higher in the TAM-sensitive group compared to the TAM-resistant group (p = 0.0002). receiver operating characteristic (ROC) curve analysis also indicated the expression of miR-182-3p (p < 0.001; area under curve (AUC): 0.753), miR-382-3p (p = 0.0028; AUC: 0.697), and miR-93 (p < 0.001; AUC: 0.762) as predictive markers for TAM resistance. Multivariate models based on miR-182-3p, miR-382-3p, and miR-93 can predict the response to hormone therapy. Measuring these miRNAs is also recommended for patients with luminal-subtype BC undergoing TAM therapy.
Indexed as
Identifiers
39754680What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.